ADVERTISEMENT
Furthering Evidence-Based Practice With Cost-Effectiveness Research
In this video, Martha R. Kelso, RN, HBOT, discusses how a recent study on the efficacy and cost-effectiveness of dHACM allografts is important for conveying to payers how important it is to cover advanced treatment modalities.
This video is part 2 of a 3-part series of videos on dHACM allografts in lower extremity diabetic ulcers. For additional content, read the Advances article here.
Transcript:
Hi, thank you for inviting me. I'm excited to talk to you guys about this groundbreaking study, I'm Martha Kelso, I'm the CEO and founder for Wound Care Plus LLC. We're one of the Midwest's largest mobile wound companies that service a lot of the outpatient extended care facilities. Thanks for having me.
For furthering evidence-based practices, this study screams to the payers that we have to have more advanced modalities in our toolbox or our toolkit to be able to heal some of these chronically stalled wounds. As a matter of fact, not having access means that we end up with longer chronicity of wounds, major amputations, and hospitalizations. So almost releasing the handcuffs and letting us have access to these products early on, regardless of the LCD--the local coverage determination--or even the payer policy that's currently in effect, we're really doing a disservice to our patients with lower extremity wounds and diabetes by not getting them access sooner. So it is statistically significant on the average number of days that we were able to cut down the heal times and the number of advanced therapy applications overall when we applied it early on and consistently with the standard of care.
